Cargando…
A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients
BACKGROUND: Multiple sclerosis (MS) is a chronic disease characterized by demyelination, glial activation and axonal degeneration in the central nervous system. At the present, there is no certain remedy for this disease. However, available therapies often attenuate disease progress. METHODS: This s...
Autores principales: | Mazdeh, Mehrdokht, Kargar Monhaser, Shahriar, Taheri, Mohammad, Ghafouri-Fard, Soudeh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451934/ https://www.ncbi.nlm.nih.gov/pubmed/30957197 http://dx.doi.org/10.1186/s40169-019-0228-7 |
Ejemplares similares
-
The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study
por: Mazdeh, Mehrdokht, et al.
Publicado: (2018) -
Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
por: Gasperini, Claudio, et al.
Publicado: (2013) -
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020) -
Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
por: Yavari, Fatemeh, et al.
Publicado: (2021) -
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)